Key Findings
CNET, a leading technology review site, has published its 2026 guide to the ‘Best Continuous Glucose Monitors (CGM),’ highlighting Dexcom Stelo, Abbott FreeStyle Libre 3 Plus, and Eversense 365 as top devices revolutionizing diabetes management. These CGM systems are recognized for their superior sensor life, high accuracy, and favorable FDA approval status. They offer real-time glucose data, customizable alerts for hypo- and hyperglycemia, and, in some cases, predictive alerts, empowering individuals with diabetes to proactively manage their condition with unprecedented insight.
Technical & Clinical Details
Each featured CGM device incorporates distinct technological advantages. For instance, Dexcom Stelo is designed to extend CGM benefits specifically to non-insulin-using Type 2 diabetes patients, complemented by a refined app experience. Abbott FreeStyle Libre 3 Plus is noted for its compact size, ease of application, and direct data transmission to smartphones. The Eversense 365 stands out as a long-term implantable sensor, offering an impressive sensor life of up to one year. The Medtronic Guardian Connect System, in addition to real-time data, provides predictive alerts for glucose fluctuations, enabling users to anticipate and respond to potential glycemic events before they occur. While all these devices require a physician’s prescription, they offer a far more comprehensive view of glucose trends compared to traditional blood glucose meters.
Background & Context
The continuous glucose monitoring (CGM) market has rapidly grown, becoming an indispensable tool for diabetes self-management and physician-guided treatment decisions. Unlike conventional finger-prick testing, CGMs provide round-the-clock tracking of glucose levels, allowing users to visualize the impact of diet, exercise, and stress on their blood sugar. This capability enables more personalized diabetes management, significantly contributing to the reduction of diabetes complications and enhancing patients’ quality of life. The global demand for such advanced biosensing technologies continues to accelerate.
Strategic Significance & Outlook
The CGM technology is expected to undergo further miniaturization, enhanced accuracy, and expanded applicability to a broader patient population, including those with non-insulin-dependent diabetes. Furthermore, the development of multi-functional sensors integrating other biomarkers, such as continuous ketone monitoring (CKM) and dual glucose-ketone sensing technologies, is underway. These advancements are poised to fundamentally transform diabetes care, accelerating the shift towards more preventive and personalized approaches. Intense competition among device manufacturers is expected to drive the introduction of even more user-friendly and high-performing products, ultimately benefiting patients worldwide.
Source: https://www.cnet.com/health/medical/best-continuous-glucose-monitors-doctor-approved/
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments